Abstract: Multiple arterial and venous thromboses are usually related to thrombophilia or antiphospholipid syndrome. Recurrent pulmonary embolism strongly indicates the presence of genetic or acquired thrombophilic factors. Simultaneous double arterial in situ thromboses are unusual, even in thrombophilic conditions. Simultaneous occurrence of pulmonary embolism and cerebrovascular ischaemic insult are highly indicative of existence of patent foramen ovale. We present herein a patient with the double simultaneous arterial thromboses as the manifestation of thrombophilia (heterozygous for methylenetetrahydrofolate-reductase (MTHFR) C677T gene mutation). There was no patent foramen ovale suspected upon the patient`s admittance to hospital. To the best of our knowledge there have been no similar cases presented to date.
Introduction
Multiple arterial and venous thromboses are usually related to thrombophilia or antiphospholipid syndrome. Recurrent pulmonary embolism strongly indicates a presence of genetic or acquired thrombophilic factors [1] . Pulmonary embolism (PE) is usually a major clinical manifestation of venous thromboembolism [2] , while in situ thrombosis in the pulmonary artery is rare and is most often related to an underlying thrombophilic condition. Factor V Leiden (FVL), prothrombin gene mutation G20210A (FII G20210), genetic variant C677T of the methylentetrahydrofolate reductase (MTHFR), as well as the polymorphism A2 (PlA2) in platelet glycoprotein IIb/IIIa and antiphospholipid syndrome have recently been discussed as possible causes of recurrent thromboses [3, 4] . The C677T variant of MTHFR has recently also been suggested as a risk factor for venous and arterial thrombosis resulting in a thermo-stable, less active enzyme form [5] .
Simultaneous double arterial in situ thromboses are unusual, even in thrombophilic conditions. Simultaneous occurrence of pulmonary embolism and cerebrovascular ischaemic insult are highly indicative of existence of patent foramen ovale6. We present an unusual case of simultaneous double arterial in situ thromboses as the manifestation of heterozygous MTH FR C677T variant.
Case report
A 63-year-old non-obese Caucasian, male, a smoker, presented to the emergency department with dizziness, fatigue, warmth in his head, feeling of an impending loss of consciousness and a mild shortness of breath. However, he had had no loss of consciousness before hospital admission.
In his past medical history, there was information on a previous pulmonary embolism that occurred eighteen years ago with concomitant deep venous thrombosis of the right calf and external iliac vein. The thrombosis was followed by therapy with oral anticoagulants at hospital discharge, but no history of underlying thrombophilia was noted at that time. Irregular therapy with oral anticoagulants was applied because the patient was uncooperative and had not had regular medical checkups. He had been feeling extreme fatigue and effort intolerance for six months before the hospital admission. He had no medical history of stroke.
The family history revealed that his sister died aged 56 from pulmonary thromboembolism.
Upon hospital admission, the patient was eupnoic, pale, had no tachycardia (pulse: 65 beats per min) with an oxygen saturation of 88% in room air and blood pressure of 150/75 mmHg. His lungs were clear to auscultation and A2 and P2 were accentuated, without cardiac murmurs. Neither of his legs were painful or swollen, and had normal pulse. Neurological examination showed a right nystagmus without rough neurological disturbances.
A standard 12 lead electrocardiogram revealed sinus rhythm, P pulmonale and inversion of the T wave from V1 to V6.
Progradient development of dyspnea was noticed in the half hour after admission, followed by incomplete right bundle branch block and a worsening of oxygen saturation, with concomitant hypertension (170/90 mmHg), but without tachycardia. An urgent transthoracic echocardiogram done at the bedside revealed significantly dilated right chambers (right ventricle 46 mm in the four-chamber view) with highly elevated end-systolic-pressure in right ventricle (ESPRV) of 171 mmHg. The right-to-left ventricle ratio was 1.11, the left ventricular ejection fraction was slightly diminished (52% according to Simpson) and flow velocity over tricuspid valve was increased (1.4 m/s).
The patient was immediately sent to undergo multislice CT pulmonary angiography, which verified the massive thrombus in the right pulmonary artery that decreased its lumen to as narrow as 7 mm. (Figure 1) The NMR of his endocranium, performed at the same time, revealed existence of new ischaemic lesions in the right hemisphere of cerebellum and the right corpus rectiformis. An old, small post-ischemic lesion was documented in the right occipital lobus, with reductive changes of frontal and parietal cortex. Brain haemorrhagy, both old and new, was excluded. (Figure 2) The blood tests showed an extremely high level of D dimer at 13,847 mcg/L (normal value <500 mcg/L); leukocytes at 15.4x106/L; a high level of hemoglobin 170 g/L; and normal platelet count (318 x109/L). Creatinine-kinase was extremely elevated at 878 U/L (normal value <190 U/L)), but troponin I was within the normal range.
After the CT and NMR diagnostics, his blood pressure started to fall to 90/60 mmHg without concomitant tachycardia. Considering the worsening of the patient`s clinical condition, arterial hypotension and the CT image of the massive pulmonary embolus, patient was defined as high-risk, with very few absolute contraindications [7] . He was immediately treated with fibrinolytic therapy (streptokinase: 1.500.000 units i.v. in the first half hour and 100.000 units/h during the next 48 hours) with continuation of anticoagulant therapy: heparin and oral anticoagulant (warfarin); a broad-spectrum antibiotic; ACEi and calcium channel blocker. Regression of the dyspnea was reported by the patient 24 hours after administration of the therapy, followed by resolution of the IRBBB and an increase in oxygen saturation. Control echocardiography revealed significantly decreased, but still high, ESPRV of 112 mmHg, improved left ventricular ejection fraction (64% according to Simpson); the right-to-left ventricle ratio was decreased to 0.81, as was the flow velocity over the tricuspid valve (1.1 m/s).
Compression Doppler ultrasonography of his distal extremities showed old phlebothrombotic changes in central venous sinus of the right muscle solei with partial recanalisation. Carotid Dopppler ultrasonography revealed no significant vulnerable plaque lesions, which could have been a source of the potentional embolus for CVI.
Considering that it was a recurrent pulmonary embolism episode followed by simultaneous arterial thrombosis in cerebrovascular system, testing for thrombophilia was performed [antithrombin III, protein C and protein S deficiency, lupus anticoagulant, anticardiolipin antibodies (ACL), factor V (FV) Leiden, FII G20210A and MTHFR C677T mutation]. A hypercoagulability profile workup showed the presence of heterozygous mutations for MTHFR (C677T). In the first attempt, anticardiolipin antibodies were mildly and non-specifically elevated. However, several repeated laboratory tests during hospitalization, as well as additional tests during a 12 month follow-up period after hospital discharge, showed normal values, excluding the diagnosis of antiphospholipid syndrome.
As the patent foramen ovale (PFO) was highly indicative for simultaneous occurrence of pulmonary embolism and cerebrovascular ischaemic insult, a transesophageal echocardiogram (TEE) was performed. Surprisingly, the TEE study with provocative Valsalva maneuver testing was negative for the presence of FOA, despite a highly elevated ESPRV of 171 mmHg, showing that the thrombosis in the cerebrovascular system was not re-embolization but a new in-situ thrombosis.
Almost complete resolution of the massive pulmonary embolism following treatment was seen on the control CT chest 7 days later. The control TEE also showed decreased ESPRV. The patient was discharged with anticoagulant therapy.
We concluded, considering all the issues mentioned previously, that our patient had had double simultaneous thromboses: a new, recurrent pulmonary embolism with concomitant pulmonary hypertension and a new cerebellum infarction with old thrombotic consequences in the deep venous system of the right calf.
We present a patient with the double simultaneous arterial thromboses, as the first recognized manifestations of thrombophilia MTHFR gene polymorphism C677T). Tachycardia and tachypnea are regarded to be among the most characteristic symptoms of pulmonary embolism. Although the patient had a massive pulmonary embolism, there was no tachycardia, hypotension or tachypnea. The absence of those symptoms was the consequence of the concomitant cerebrovascular insult, masking the clinical presentation of PE.
A pulmonary embolus, especially a large one, may be a proximate cause of increased pulmonary artery pressure that retrogradely propagates to the right ventricle and the right atrium, causing a gradient of pressure across the PFO and leading to the right-toleft shunt. This case is unusual since there was no PFO blamed for the cerebral embolisation presented as cerebellum infarction, but the double simultaneous in-situ arterial thromboses were the manifestation of the underlying thrombophilic condition.
Conclusion
This case is quite unusual: it demonstrates in remarkable detail the pathological mechanism underlying double simultaneous arterial thromboses as the manifestation of thrombophilia (heterozygous MTHFR) gene polymorphism C677T). To the best of our knowledge, this is the first reported case of double simultaneous arterial in-situ thromboses in heterozygous MTHFR. It should be kept in mind that in case of a recurrent pulmonary embolism episode followed by simultaneous arterial thrombosis in cerebrovascular system, testing for MTHFR should always be performed.
